Can-Fite BioPharma Ltd. CANF 深 沪
等待开盘 12-19 09:30:00 美东时间
0.25
-0.024
-8.63%
华盛通- 最 高0.2695
- 今 开0.26
- 成交量 166.90万股
- 最 低 0.2455
- 昨 收 0.2736
- 总市值 321.93万
- 52周最高 2.33
- 市盈率 静 --
- 换手率 12.96%
- 52周最低 0.2455
- 委 比 0.00%
- 总股本 1287.72万
- 历史最高 1419.00
- 量 比 1.92
- 振 幅 8.77%
- 历史最低 0.2455
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
D. Boral Capital Maintains Buy on Can Fite Biofarma, Lowers Price Target to $4
D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and lowers the price target from $11 to $4.
12-17 20:42
Can-Fite BioPharma Updates on Clinical Trials and Financials
Can-Fite BioPharma ( ($CANF) ) has provided an update. On December 16, 2025, Ca...
12-16 22:58
Can-Fite BioPharma Advances Multiple Phase II/III Trials For Namodenoson And Piclidenoson; Reports $13.65M Cash Position
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced an update on its
12-16 22:19
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 12.1% to $8.18 during Mond...
11-25 05:05
Can-Fite Secures Brazilian Patent for Erectile Dysfunction Drug Candidate CF602
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today it received a
11-20 20:04
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target
D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $11 price target.
11-19 03:30
Can-Fite BioPharma Announces Patients Treated With Namodenoson Reaches Overall Survival Of 9 Years With Complete Response
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today that a patient
11-18 20:05
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
